In April 2025, the FDA granted orphan drug designation to spesolimab-sbzo for the treatment of pyoderma gangrenosum. This ...

Trump is pushing drug companies to lower their prices, but experts cast doubt on how effective this endeavor will prove.

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

In this video, Philip J. Mease, MD, discusses results from phase 3 clinical trials of deucravacitinib for psoriatic arthritis, presented at the EULAR 2025 Congress.

The FDA granted priority review to the application and will decide whether to approve the treatment by Dec. 5.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

U.S. drugmaker Pfizer on Tuesday raised its full-year profit forecast on strong demand for its heart disease drug, Vyndaqel, ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...